Summit Corporation PLC : Exercise of Warrants

Accessibility: Skip TopNav

August 23, 2013 09:30 ET

Summit Therapeutics plc

Summit Therapeutics plc

Summit Corporation plc

("Summit" or "the Company")

EXERCISE OF WARRANTS

Oxford, UK, 23 August 2013, Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, announces that it has received notice and payment from N+1 Singer Capital Markets ('N+1') to exercise warrants over 1,000,000 Ordinary shares of 1.0 pence each at an exercise price of 5.0 pence per Ordinary share.

Summit has applied for admission of the new Ordinary shares to trading on AIM ('Admission'), a market of the London Stock Exchange.  It is expected that Admission will become effective on or around 29 August 2013 and the new Ordinary shares will rank pari passu with existing Ordinary shares.  Following Admission, the Company will have 447,357,841 Ordinary shares in issue.

Summit is an Oxford, UK based drug discovery and development Company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection.  Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and follow Summit on Twitter (@summitplc).

For more information, please contact: